Literature DB >> 15870070

The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code.

Jason E Fish1, Charles C Matouk, Alisa Rachlis, Steven Lin, Sharon C Tai, Cheryl D'Abreo, Philip A Marsden.   

Abstract

Expression of endothelial nitric-oxide synthase (eNOS) mRNA is highly restricted to the endothelial cell layer of medium to large sized arterial blood vessels. Here we assessed the chromatin environment of the eNOS gene in expressing and nonexpressing cell types. Within endothelial cells, but not a variety of nonendothelial cells, the nucleosomes that encompassed the eNOS core promoter and proximal downstream coding regions were highly enriched in acetylated histones H3 and H4 and methylated lysine 4 of histone H3. This differentially modified chromatin domain was selectively associated with functionally competent RNA polymerase II complexes. Endothelial cells were particularly enriched in acetylated histone H3 lysine 9, histone H4 lysine 12, and di- and tri-methylated lysine 4 of histone H3 at the core promoter. Histone modifications at this region, which we have previously demonstrated to exhibit cell-specific DNA methylation, were functionally relevant to eNOS expression. Inhibition of histone deacetylase activity by trichostatin A increased acetylation of histones H3 and H4 at the eNOS proximal promoter in nonexpressing cell types and led to increased steady-state eNOS mRNA transcript levels. H3 lysine 4 methylation was also essential for eNOS expression, since treatment of endothelial cells with methylthioadenosine, a known lysine 4 methylation inhibitor, decreased eNOS RNA levels, H3 lysine 4 methylation, and RNA polymerase II loading at the eNOS proximal promoter. Importantly, methylthioadenosine also prevented the trichostatin A-mediated increase in eNOS mRNA transcript levels in nonendothelial cells. Taken together, these findings provide strong evidence that the endothelial cell-specific expression of eNOS is controlled by cell-specific histone modifications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870070     DOI: 10.1074/jbc.M502115200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.

Authors:  Andrew Advani; Qingling Huang; Kerri Thai; Suzanne L Advani; Kathryn E White; Darren J Kelly; Darren A Yuen; Kim A Connelly; Philip A Marsden; Richard E Gilbert
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Epigenetic programming and risk: the birthplace of cardiovascular disease?

Authors:  Maria Cristina Vinci; Gianluca Polvani; Maurizio Pesce
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 3.  Virchow's triad: the vascular basis of cerebral injury.

Authors:  Gregory J del Zoppo
Journal:  Rev Neurol Dis       Date:  2008

Review 4.  Epigenetic mechanisms in diabetic vascular complications.

Authors:  Marpadga A Reddy; Rama Natarajan
Journal:  Cardiovasc Res       Date:  2011-01-25       Impact factor: 10.787

5.  Endothelial dysfunction in children with obstructive sleep apnea is associated with epigenetic changes in the eNOS gene.

Authors:  Leila Kheirandish-Gozal; Abdelnaby Khalyfa; David Gozal; Rakesh Bhattacharjee; Yang Wang
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

6.  Relative reduction of endothelial nitric-oxide synthase expression and transcription in atherosclerosis-prone regions of the mouse aorta and in an in vitro model of disturbed flow.

Authors:  Doyon Won; Su-Ning Zhu; Mian Chen; Anouk-Martine Teichert; Jason E Fish; Charles C Matouk; Michael Bonert; Matadial Ojha; Philip A Marsden; Myron I Cybulsky
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

7.  Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1.

Authors:  Olivia I Koues; R Kyle Dudley; Agnieszka D Truax; Dawson Gerhardt; Kavita P Bhat; Sam McNeal; Susanna F Greer
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

8.  The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.

Authors:  Robert P Hebbel; Gregory M Vercellotti; Betty S Pace; Anna N Solovey; Rahn Kollander; Chine F Abanonu; Julia Nguyen; Julie V Vineyard; John D Belcher; Fuad Abdulla; Shadé Osifuye; John W Eaton; Robert J Kelm; Arne Slungaard
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

9.  Disrupted NOS signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow.

Authors:  Sanjeev A Datar; Wenhui Gong; Youping He; Michael Johengen; Rebecca J Kameny; Gary W Raff; Emin Maltepe; Peter E Oishi; Jeffrey R Fineman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-13       Impact factor: 4.733

10.  VE-statin/egfl7 expression in endothelial cells is regulated by a distal enhancer and a proximal promoter under the direct control of Erg and GATA-2.

Authors:  Alexandra Le Bras; Chantal Samson; Matteo Trentini; Bertrand Caetano; Etienne Lelievre; Virginie Mattot; Friedrich Beermann; Fabrice Soncin
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.